EA031627B1 - Модуляторы аденозиновых рецепторов a - Google Patents
Модуляторы аденозиновых рецепторов a Download PDFInfo
- Publication number
- EA031627B1 EA031627B1 EA201791657A EA201791657A EA031627B1 EA 031627 B1 EA031627 B1 EA 031627B1 EA 201791657 A EA201791657 A EA 201791657A EA 201791657 A EA201791657 A EA 201791657A EA 031627 B1 EA031627 B1 EA 031627B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cyano
- ylcarbamoyl
- thiazol
- carboxylic acid
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201530085A ES2578363B1 (es) | 2015-01-22 | 2015-01-22 | Moduladores de los receptores A3 de adenosina |
PCT/ES2016/070032 WO2016116652A1 (es) | 2015-01-22 | 2016-01-22 | Moduladores de los receptores a3 de adenosina |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791657A1 EA201791657A1 (ru) | 2017-12-29 |
EA031627B1 true EA031627B1 (ru) | 2019-01-31 |
Family
ID=55359537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791657A EA031627B1 (ru) | 2015-01-22 | 2016-01-22 | Модуляторы аденозиновых рецепторов a |
Country Status (22)
Country | Link |
---|---|
US (1) | US10238637B2 (es) |
EP (1) | EP3248964B1 (es) |
JP (1) | JP6637983B2 (es) |
KR (1) | KR102424575B1 (es) |
CN (1) | CN107207445B (es) |
AU (1) | AU2016210091B2 (es) |
BR (1) | BR112017015597B1 (es) |
CA (1) | CA2974596C (es) |
CY (1) | CY1122172T1 (es) |
DK (1) | DK3248964T3 (es) |
EA (1) | EA031627B1 (es) |
ES (2) | ES2578363B1 (es) |
HR (1) | HRP20191779T1 (es) |
HU (1) | HUE046307T2 (es) |
LT (1) | LT3248964T (es) |
ME (1) | ME03570B (es) |
MX (1) | MX2017009514A (es) |
PL (1) | PL3248964T3 (es) |
PT (1) | PT3248964T (es) |
RS (1) | RS59388B1 (es) |
SI (1) | SI3248964T1 (es) |
WO (1) | WO2016116652A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
KR102155406B1 (ko) | 2017-08-18 | 2020-09-11 | 주식회사 엘지화학 | 아연철산화물 내 잔류 Cl의 정량분석 방법 |
US11458974B2 (en) * | 2019-07-08 | 2022-10-04 | Toyota Motor Engineering & Manufacturing North America, Inc. | Fleet-based average lane change and driver-specific behavior modelling for autonomous vehicle lane change operation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124000A2 (en) * | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンa3受容体拮抗剤およびチアゾール化合物 |
US6303619B1 (en) | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
WO1999064418A1 (en) | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
DE69924254D1 (de) | 1998-07-16 | 2005-04-21 | Univ Pennsylvania | Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks |
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
BR0009952A (pt) | 1999-04-23 | 2002-03-26 | Takeda Chemical Industres Ltd | Composto, pró-droga, processo para produzir um composto, composição farmacêutica, método para antagonizar um receptor de adenosina a3, para inibir a p38 map quinase e a produção de tnf-alfa e para prevenir ou tratar doenças, e uso de um composto |
DE60136530D1 (de) | 2000-03-01 | 2008-12-24 | Janssen Pharmaceutica Nv | 2,4-disubstituierte thiazolyl derivate |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
SK14142003A3 (sk) | 2001-05-31 | 2005-03-04 | Sanofi-Aventis | Aminochinolínové a aminopyridínové deriváty a ich použitie ako adenozínových A3 ligandov |
CA2453611A1 (en) | 2001-07-16 | 2003-01-30 | Maytag Corporation | Refrigerator shelves with rolled hook for cantilever fastening |
HUP0105406A3 (en) | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
WO2005009969A1 (en) | 2003-07-31 | 2005-02-03 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
US7718808B2 (en) | 2003-12-26 | 2010-05-18 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
JP5414277B2 (ja) | 2006-01-26 | 2014-02-12 | ザ・ガバメント・オブ・ジ・ユナイテッド・ステイツ・オブ・アメリカ・レプリゼンテッド・バイ・ザ・セクレタリー・ディパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ | A3アデノシンレセプタ・アロステリックモジュレータ |
WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
WO2008006369A1 (en) | 2006-07-14 | 2008-01-17 | Santaris Pharma A/S | Adenosine receptor antagonists |
WO2008045330A2 (en) | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
US20090099212A1 (en) | 2007-10-16 | 2009-04-16 | Jeff Zablocki | A3 adenosine receptor antagonists |
US7973051B2 (en) | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
JP2011528363A (ja) | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アテローム性動脈硬化症の治療 |
JP5431476B2 (ja) | 2008-08-01 | 2014-03-05 | アメリカ合衆国 | A3アデノシン受容体アンタゴニストおよびa3アデノシン受容体部分アゴニスト |
WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
-
2015
- 2015-01-22 ES ES201530085A patent/ES2578363B1/es active Active
-
2016
- 2016-01-22 KR KR1020177023348A patent/KR102424575B1/ko active IP Right Grant
- 2016-01-22 PL PL16704680T patent/PL3248964T3/pl unknown
- 2016-01-22 LT LTEP16704680.4T patent/LT3248964T/lt unknown
- 2016-01-22 ME MEP-2019-265A patent/ME03570B/me unknown
- 2016-01-22 WO PCT/ES2016/070032 patent/WO2016116652A1/es active Application Filing
- 2016-01-22 EA EA201791657A patent/EA031627B1/ru not_active IP Right Cessation
- 2016-01-22 RS RSP20191282 patent/RS59388B1/sr unknown
- 2016-01-22 MX MX2017009514A patent/MX2017009514A/es active IP Right Grant
- 2016-01-22 AU AU2016210091A patent/AU2016210091B2/en active Active
- 2016-01-22 US US15/544,429 patent/US10238637B2/en active Active
- 2016-01-22 HU HUE16704680A patent/HUE046307T2/hu unknown
- 2016-01-22 CA CA2974596A patent/CA2974596C/en active Active
- 2016-01-22 PT PT167046804T patent/PT3248964T/pt unknown
- 2016-01-22 ES ES16704680T patent/ES2750030T3/es active Active
- 2016-01-22 CN CN201680006653.8A patent/CN107207445B/zh active Active
- 2016-01-22 SI SI201630442T patent/SI3248964T1/sl unknown
- 2016-01-22 DK DK16704680.4T patent/DK3248964T3/da active
- 2016-01-22 EP EP16704680.4A patent/EP3248964B1/en active Active
- 2016-01-22 BR BR112017015597-4A patent/BR112017015597B1/pt active IP Right Grant
- 2016-01-22 JP JP2017538582A patent/JP6637983B2/ja active Active
-
2019
- 2019-10-01 HR HRP20191779TT patent/HRP20191779T1/hr unknown
- 2019-10-11 CY CY20191101070T patent/CY1122172T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124000A2 (en) * | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
Non-Patent Citations (4)
Title |
---|
BHATTACHARYA, P. LEONARD, J.T. ROY, K.: "Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A"3 receptor antagonists using FA and GFA techniques", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 4, 15 February 2005 (2005-02-15), GB, pages 1159 - 1165, XP004776019, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2004.11.022 * |
BORGHINI, A. PIETRA, D. DOMENICHELLI, P. BIANUCCI, A.M.: "QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A"1 and A"3 receptors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 18, 15 September 2005 (2005-09-15), GB, pages 5330 - 5337, XP005021037, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2005.05.041 * |
INAMDAR GAJANAN S.; PANDYA AMIT N.; THAKAR HARDIK M.; SUDARSANAM VASUDEVAN; KACHLER SONJA; SABBADIN DAVIDE; MORO STEFANO; KLOTZ KA: "New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS., FR, vol. 63, 22 March 2013 (2013-03-22), FR, pages 924 - 934, XP029234025, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2013.03.020 * |
MUIJLWIJK-KOEZEN VAN J E, ET AL: "Thiazole and Thiadiazole Analogues as a Novel class of Adenosine Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 5, 1 March 2001 (2001-03-01), pages 749 - 762, XP002318825, ISSN: 0022-2623, DOI: 10.1021/jm0003945 * |
Also Published As
Publication number | Publication date |
---|---|
PT3248964T (pt) | 2019-10-28 |
BR112017015597B1 (pt) | 2023-02-28 |
JP6637983B2 (ja) | 2020-01-29 |
AU2016210091B2 (en) | 2019-08-15 |
CN107207445B (zh) | 2021-03-16 |
AU2016210091A1 (en) | 2017-08-17 |
SI3248964T1 (sl) | 2019-11-29 |
BR112017015597A2 (pt) | 2018-03-13 |
KR20170104612A (ko) | 2017-09-15 |
EA201791657A1 (ru) | 2017-12-29 |
RS59388B1 (sr) | 2019-11-29 |
ES2578363B1 (es) | 2017-01-31 |
JP2018502881A (ja) | 2018-02-01 |
CA2974596A1 (en) | 2016-07-28 |
ES2578363A1 (es) | 2016-07-26 |
ME03570B (me) | 2020-07-20 |
ES2750030T3 (es) | 2020-03-24 |
EP3248964A1 (en) | 2017-11-29 |
US10238637B2 (en) | 2019-03-26 |
LT3248964T (lt) | 2019-10-10 |
HUE046307T2 (hu) | 2020-02-28 |
EP3248964B1 (en) | 2019-07-17 |
HRP20191779T1 (hr) | 2019-12-27 |
CY1122172T1 (el) | 2020-11-25 |
US20180263963A1 (en) | 2018-09-20 |
DK3248964T3 (da) | 2019-10-07 |
CN107207445A (zh) | 2017-09-26 |
MX2017009514A (es) | 2017-11-15 |
CA2974596C (en) | 2022-11-08 |
WO2016116652A1 (es) | 2016-07-28 |
KR102424575B1 (ko) | 2022-07-25 |
PL3248964T3 (pl) | 2020-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102117453B1 (ko) | 5-아릴알키닐기에 의해 치환된 벤즈아미드계 화합물 및 이의 제조방법, 약물 조성물과 용도 | |
PT1373191E (pt) | Indanilaminas aciladas e sua utilização como fármacos | |
KR102424575B1 (ko) | 아데노신 a₃수용체의 조절제 | |
KR102483091B1 (ko) | 아데노신 a3 수용체의 조절제 | |
BR112019012464B1 (pt) | Compostos moduladores dos receptores a3 de adenosina, composição farmacêutica, uso e combinação | |
IL293388A (en) | History of benzylamide as a transforming growth factor inhibitor in the i/alk5 receptor cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |